{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nervous+System+Cancer&page=6",
    "query": {
      "condition": "Nervous System Cancer",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 3923,
    "total_pages": 393,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nervous+System+Cancer&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Nervous+System+Cancer&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-20T06:35:27.156Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05048212",
      "title": "A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain Metastases",
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2022-09-20",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-11-20T06:35:27.156Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05048212"
    },
    {
      "nct_id": "NCT00241722",
      "title": "Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bowel Dysfunction",
        "Constipation"
      ],
      "interventions": [
        {
          "name": "Alvimopan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 805,
      "start_date": "2005-08-01",
      "completion_date": "2007-02-01",
      "has_results": false,
      "last_update_posted_date": "2017-08-30",
      "last_synced_at": "2026-11-20T06:35:27.156Z",
      "location_count": 143,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 120 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00241722"
    },
    {
      "nct_id": "NCT01347307",
      "title": "Stereotactic Body Radiotherapy for Spine Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Spinal Metastases",
        "Vertebral Metastases",
        "Benign Spinal Tumors",
        "Chordoma",
        "Meningioma",
        "Schwannoma",
        "Neurofibroma",
        "Paragangliomas",
        "Arteriovenous Malformations"
      ],
      "interventions": [
        {
          "name": "SBRT for Benign Extradural Spine Tumors",
          "type": "RADIATION"
        },
        {
          "name": "SBRT for Vertebral/Paraspinal Metastases",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Mercy Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2008-09",
      "completion_date": "2017-09",
      "has_results": true,
      "last_update_posted_date": "2020-06-18",
      "last_synced_at": "2026-11-20T06:35:27.156Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01347307"
    },
    {
      "nct_id": "NCT05307328",
      "title": "SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cushing's Syndrome I",
        "Cushing Disease Due to Increased ACTH Secretion",
        "Cortisol Excess",
        "Cortisol; Hypersecretion",
        "Cortisol Overproduction",
        "Ectopic ACTH Secretion"
      ],
      "interventions": [
        {
          "name": "SPI-62",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sparrow Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2022-09-01",
      "completion_date": "2025-08-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-08",
      "last_synced_at": "2026-11-20T06:35:27.156Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Fort Myers, Florida • Rochester, Minnesota + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Henderson",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05307328"
    },
    {
      "nct_id": "NCT00916409",
      "title": "Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "NovoTTF-100A device",
          "type": "DEVICE"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "NovoCure Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 700,
      "start_date": "2009-06",
      "completion_date": "2017-03",
      "has_results": false,
      "last_update_posted_date": "2017-04-10",
      "last_synced_at": "2026-11-20T06:35:27.156Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00916409"
    },
    {
      "nct_id": "NCT02309099",
      "title": "Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Unilateral Acoustic Neuroma",
        "Meniere's Disease"
      ],
      "interventions": [
        {
          "name": "Cochlear Implant",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 10,
      "start_date": "2014-11",
      "completion_date": "2017-11-08",
      "has_results": true,
      "last_update_posted_date": "2019-01-07",
      "last_synced_at": "2026-11-20T06:35:27.156Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02309099"
    },
    {
      "nct_id": "NCT07374692",
      "title": "Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Recurrent CNS Tumors",
        "Brain Cancer",
        "Gliomas",
        "IDH-wildtype Gliomas",
        "IDH-mutant Gliomas",
        "Rare CNS Tumor"
      ],
      "interventions": [
        {
          "name": "SmartMatch testing",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "15 Years to 120 Years"
      },
      "enrollment_count": 4,
      "start_date": "2026-02-04",
      "completion_date": "2026-09-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-11-20T06:35:27.156Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07374692"
    },
    {
      "nct_id": "NCT00045734",
      "title": "Imatinib Mesylate in Treating Patients With Recurrent Meningioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Grade I Meningioma",
        "Adult Grade II Meningioma",
        "Adult Grade III Meningioma",
        "Adult Meningeal Hemangiopericytoma",
        "Adult Meningioma",
        "Recurrent Adult Brain Tumor"
      ],
      "interventions": [
        {
          "name": "imatinib mesylate",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2003-02",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2017-05-15",
      "last_synced_at": "2026-11-20T06:35:27.156Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • San Francisco, California • Bethesda, Maryland + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00045734"
    },
    {
      "nct_id": "NCT02942264",
      "title": "Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Brain Tumor",
        "Astrocytoma",
        "Astroglioma",
        "Glioblastoma",
        "Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "Zotiraciclib (TG02)",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide (TMZ)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2016-12-14",
      "completion_date": "2020-08-26",
      "has_results": true,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-11-20T06:35:27.156Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02942264"
    },
    {
      "nct_id": "NCT02389309",
      "title": "Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Recurrent Brain Neoplasm",
        "Recurrent Malignant Solid Neoplasm",
        "Refractory Brain Neoplasm"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "12 Months to 20 Years"
      },
      "enrollment_count": 14,
      "start_date": "2015-10-05",
      "completion_date": "2027-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-11-20T06:35:27.156Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02389309"
    }
  ]
}